Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer.
Zhou Q, Chen W, Fan Z, Chen Z, Liang J, Zeng G, Liu L, Liu W, Yang T, Cao X, Yu B, Xu M, Chen YG, Chen L.
Zhou Q, et al. Among authors: chen z, chen yg, chen l, chen w.
Theranostics. 2021 May 3;11(13):6592-6606. doi: 10.7150/thno.59816. eCollection 2021.
Theranostics. 2021.
PMID: 33995678
Free PMC article.